Prostate-specificantigen (PSA) is a well-known clinical biomarkerin prostate cancer (PCa) diagnosis, but a better test is still needed,as the serum-level-based PSA quantification exhibits limited specificityand comes with poor predictive value. The gene discussed is KLK3; the disease is prostate carcinoma.